CY1105381T1 - Αλατα βορονικου οξεως - Google Patents

Αλατα βορονικου οξεως

Info

Publication number
CY1105381T1
CY1105381T1 CY20061100903T CY061100903T CY1105381T1 CY 1105381 T1 CY1105381 T1 CY 1105381T1 CY 20061100903 T CY20061100903 T CY 20061100903T CY 061100903 T CY061100903 T CY 061100903T CY 1105381 T1 CY1105381 T1 CY 1105381T1
Authority
CY
Cyprus
Prior art keywords
boronic acid
acid salts
salts
mpg
counterion
Prior art date
Application number
CY20061100903T
Other languages
English (en)
Inventor
David Jonathan Madge
Mark Dolman
Sophie Marie Combe-Marzelle
John Joseph Deadman
Anthony James Kennedy
Sanjay Kumar Kakkar
Original Assignee
Trigen Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0220764A external-priority patent/GB0220764D0/en
Priority claimed from GB0220822A external-priority patent/GB0220822D0/en
Priority claimed from GB0307817A external-priority patent/GB0307817D0/en
Priority claimed from GB0311237A external-priority patent/GB0311237D0/en
Priority claimed from GB0315691A external-priority patent/GB0315691D0/en
Application filed by Trigen Limited filed Critical Trigen Limited
Publication of CY1105381T1 publication Critical patent/CY1105381T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Άλατα ενός πεπτιδικού βορονικού οξέος φαρμάκου, για παράδειγμα το Cbz-(R)-Phe-(S)-Pro-(R) - Mpg-B(OH)2. Το αντι-ιόν προς το βορονικό είδος ενδέχεται να είναι αλκαλικά μέταλα ή να προέρχεται από ένα οργανικό μείγμα που να περιέχει άζωτο. Τα άλατα χρησιμοποιούνται για την κατασκευή μίας μεθόδου για την θεραπεία της θρόμβωσης.
CY20061100903T 2002-09-09 2006-07-03 Αλατα βορονικου οξεως CY1105381T1 (el)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0220764A GB0220764D0 (en) 2002-09-09 2002-09-09 Boropeptides
GB0220822A GB0220822D0 (en) 2002-09-09 2002-09-09 Boropeptides
GB0307817A GB0307817D0 (en) 2003-04-04 2003-04-04 Boronic acid compounds
GB0311237A GB0311237D0 (en) 2003-05-16 2003-05-16 Boronic acid compounds
GB0315691A GB0315691D0 (en) 2003-07-04 2003-07-04 Boropeptides
US48578603P 2003-07-08 2003-07-08

Publications (1)

Publication Number Publication Date
CY1105381T1 true CY1105381T1 (el) 2010-07-28

Family

ID=31721886

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100903T CY1105381T1 (el) 2002-09-09 2006-07-03 Αλατα βορονικου οξεως

Country Status (20)

Country Link
EP (8) EP1695712A3 (el)
JP (3) JP2006503903A (el)
KR (2) KR20050057294A (el)
CN (2) CN100447151C (el)
AT (3) ATE325611T1 (el)
AU (3) AU2003263333A1 (el)
BR (1) BR0314450A (el)
CA (3) CA2536010A1 (el)
CY (1) CY1105381T1 (el)
DE (3) DE60304956T2 (el)
DK (2) DK1396270T3 (el)
ES (2) ES2263924T3 (el)
HK (1) HK1063154A1 (el)
IL (1) IL167294A (el)
MX (2) MXPA05002661A (el)
NZ (2) NZ539333A (el)
PL (2) PL376439A1 (el)
PT (1) PT1396270E (el)
SI (2) SI1396270T1 (el)
WO (3) WO2004022071A1 (el)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0405272D0 (en) * 2004-03-09 2004-04-21 Trigen Ltd Compounds
GB0405267D0 (en) * 2004-03-09 2004-04-21 Trigen Ltd Compounds
GB0405280D0 (en) * 2004-03-09 2004-04-21 Trigen Ltd Compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
WO2006059082A1 (en) * 2004-11-30 2006-06-08 Trigen Limited Oxidised lipids as reversal agents for boronic acid drugs
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
GB0515003D0 (en) * 2005-07-21 2005-08-31 Univ Aston Medical devices and coatings therefor
WO2009026430A2 (en) * 2007-08-21 2009-02-26 Alza Corporation Liposome formulations of boronic acid compounds
KR20100095507A (ko) * 2007-08-21 2010-08-31 알자 코퍼레이션 보론산 화합물의 생체내 투여를 위한 리포좀 조성물
WO2009139864A2 (en) * 2008-05-13 2009-11-19 The Regents Of The University Of California Fluorescence detection of poison oak oil
BRPI0915300C1 (pt) 2008-06-17 2021-05-25 Millennium Pharm Inc compostos de éster boronato e composições farmacêuticas dos mesmos
KR20110108330A (ko) * 2008-11-21 2011-10-05 이로코 카디오, 엘엘씨 혈소판감소증 및 혈소판감소증-관련 사망을 감소시키기 위한 티로피반의 약학적으로 허용가능한 염
EP2399129B1 (en) 2009-02-20 2015-11-25 Michael P. Lisanti A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
CN101928329B (zh) * 2009-06-19 2013-07-17 北京大学 三肽硼酸(酯)类化合物、其制备方法和应用
GB2523211B (en) 2012-01-27 2020-03-18 Univ Jefferson MCT protein inhibitor-related prognostic and therapeutic methods
US10022372B2 (en) 2013-04-19 2018-07-17 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
ES2761774T3 (es) * 2014-10-01 2020-05-21 Merck Patent Gmbh Derivados del ácido borónico
EP4257191A3 (en) 2016-06-21 2023-11-22 Orion Ophthalmology LLC Heterocyclic prolinamide derivatives
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
CN109187155B (zh) * 2018-07-27 2021-08-13 临沂大学 一种水样中有效硼的提取纯化方法和一种硼同位素组成的测试方法
KR102104507B1 (ko) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법
CN113121666B (zh) * 2021-03-10 2023-09-12 厦门大学 抗菌肽Scybaumancin105-127及其应用
CN114106346B (zh) * 2021-10-29 2023-04-18 重庆第二师范学院 一种稀土双金属电致化学发光材料及其制备方法和应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5856695A (ja) 1981-09-28 1983-04-04 Nitto Boseki Co Ltd 新規なトロンビン測定用基質
US4499082A (en) * 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4935493A (en) 1987-10-06 1990-06-19 E. I. Du Pont De Nemours And Company Protease inhibitors
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5574014A (en) 1988-04-28 1996-11-12 Thrombosis Research Institute Inhibitors of trypsin-like enzymes
NZ229053A (en) 1988-05-11 1990-12-21 Du Pont Pharmaceutical compositions comprising a protein or peptide and an alpha-aminoboronic acid derivative to stabilise and improve the delivery of the protein or peptide
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US5288707A (en) 1990-08-13 1994-02-22 Sandoz Ltd. Borolysine peptidomimetics
GB9017694D0 (en) * 1990-08-13 1990-09-26 Sandoz Ltd Improvements in or relating to organic chemistry
GB9024129D0 (en) * 1990-11-06 1990-12-19 Thrombosis Research Trust Inhibitors and substrates of thrombin
US5648338A (en) 1990-11-06 1997-07-15 Thrombosis Research Institute Inhibitors and substrates of thrombin
WO1992019707A1 (en) 1991-04-30 1992-11-12 The Procter & Gamble Company Liquid detergents with an aryl boronic acid
GB9224702D0 (en) 1992-11-25 1993-01-13 Thrombosis Res Inst Boronic ester synthesis
FR2701951B1 (fr) * 1993-02-24 1995-06-09 Adir Nouveaux derives peptidiques de l'acide boronique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
MY131622A (en) 1993-03-03 2007-08-30 Novartis Ag Organic compounds
US5563127A (en) 1993-03-24 1996-10-08 The Dupont Merck Pharmaceutical Company Boronic acid and ester inhibitors of thrombin
WO1994021650A1 (en) * 1993-03-24 1994-09-29 The Du Pont Merck Pharmaceutical Company Boronic acid and ester inhibitors of thrombin
US5384410A (en) * 1993-03-24 1995-01-24 The Du Pont Merck Pharmaceutical Company Removal of boronic acid protecting groups by transesterification
US5658885A (en) 1993-04-27 1997-08-19 The Dupont Merck Pharmaceutical Company Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes
IL109319A0 (en) 1993-04-27 1994-07-31 Du Pont Merck Pharma Amidino and guanidino substituted boronic acid compounds
SE9900043D0 (sv) 1999-01-11 1999-01-11 Astra Ab New use
US5681978A (en) * 1993-07-07 1997-10-28 Washington State University Research Foundation Method for the stereocontrolled synthesis of stegobinone and useful borane intermediates
US5462964A (en) * 1993-10-20 1995-10-31 The Du Pont Merck Pharmaceutical Company Dipeptide boronic acid inhibitors of trypsin-like enzymes
IL111176A0 (en) * 1993-10-07 1994-12-29 Du Pont Merck Pharma Dipeptide boronic acid inhibitors of trypsin-like enzymes and pharmaceutical compositions containing them
IL111175A0 (en) * 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
CA2174311A1 (en) * 1993-10-07 1995-04-13 Gregory James Pacofsky Boropeptide inhibitors of thrombin which contain a substituted pyrrolidine ring
US5431842A (en) 1993-11-05 1995-07-11 The Procter & Gamble Company Liquid detergents with ortho-substituted phenylboronic acids for inhibition of proteolytic enzyme
GB9401483D0 (en) 1994-01-26 1994-03-23 Sandoz Ltd Organic compounds
FR2721611B1 (fr) 1994-06-22 1996-09-27 Adir Nouveaux dérivés peptidiques de l'acide boronique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent .
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
JPH10511957A (ja) 1995-01-05 1998-11-17 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ ミシガン 表面改質ナノ微粒子並びにその製造及び使用方法
GB9502985D0 (en) 1995-02-16 1995-04-05 Thrombosis Res Inst Enzyme inhibitors
GB9515489D0 (en) 1995-07-28 1995-09-27 Sandoz Ltd Organic compounds
GB9613718D0 (en) 1996-06-29 1996-08-28 Thrombosis Res Inst Thrombin inhibitors
GB9724786D0 (en) * 1997-11-25 1998-01-21 Danbiosyst Uk Oral delivery system
CA2376965A1 (en) 1999-07-07 2001-01-11 Timothy Patrick Forsyth Peptide boronic acid inhibitors of hepatitis c virus protease
SE9904483D0 (sv) 1999-12-08 1999-12-08 Astra Ab New use
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
JP4162491B2 (ja) * 2001-01-25 2008-10-08 アメリカ合衆国 ボロン酸化合物製剤
DE10133786A1 (de) 2001-07-16 2003-02-06 Boehringer Ingelheim Pharma Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis

Also Published As

Publication number Publication date
JP2006511593A (ja) 2006-04-06
EP1695712A2 (en) 2006-08-30
AU2003263333A1 (en) 2004-03-29
WO2004022071A1 (en) 2004-03-18
CN100553639C (zh) 2009-10-28
MXPA05002661A (es) 2005-08-19
SI1396270T1 (sl) 2006-10-31
PT1396270E (pt) 2006-08-31
PL376535A1 (pl) 2006-01-09
JP2006509034A (ja) 2006-03-16
ES2263924T3 (es) 2006-12-16
IL167294A (en) 2008-11-03
EP1695712A3 (en) 2008-01-09
KR20050057295A (ko) 2005-06-16
NZ539334A (en) 2007-11-30
DE60304956D1 (de) 2006-06-08
EP1561466A3 (en) 2006-08-23
NZ539333A (en) 2007-02-23
MXPA05002662A (es) 2005-09-20
DE60304956T2 (de) 2007-01-25
CA2535792A1 (en) 2004-03-18
DK1396270T3 (da) 2006-08-28
DE60305113D1 (de) 2006-06-14
SI1400245T1 (sl) 2006-10-31
PL376439A1 (en) 2005-12-27
WO2004022070A1 (en) 2004-03-18
EP1396270A1 (en) 2004-03-10
EP1396269A1 (en) 2004-03-10
EP1466916A1 (en) 2004-10-13
DE60305113T2 (de) 2006-12-07
AU2003263343A1 (en) 2004-03-29
EP1400245A1 (en) 2004-03-24
ES2264515T3 (es) 2007-01-01
ATE324899T1 (de) 2006-06-15
AU2003263328A1 (en) 2004-03-29
JP2006503903A (ja) 2006-02-02
ATE325611T1 (de) 2006-06-15
CN100447151C (zh) 2008-12-31
EP1695711A2 (en) 2006-08-30
BR0314450A (pt) 2005-07-26
KR20050057294A (ko) 2005-06-16
CN1684693A (zh) 2005-10-19
EP1396270B1 (en) 2006-05-10
ATE376551T1 (de) 2007-11-15
CA2536010A1 (en) 2004-03-18
HK1063154A1 (en) 2004-12-17
EP1561466A2 (en) 2005-08-10
EP1695711A3 (en) 2008-01-02
EP1466916B1 (en) 2007-10-24
EP1466917A1 (en) 2004-10-13
DE60317039T2 (de) 2008-07-31
WO2004022072A1 (en) 2004-03-18
CA2535788A1 (en) 2004-03-18
DK1400245T3 (da) 2006-08-28
DE60317039D1 (de) 2007-12-06
EP1400245B1 (en) 2006-05-03
CN1681517A (zh) 2005-10-12

Similar Documents

Publication Publication Date Title
CY1105381T1 (el) Αλατα βορονικου οξεως
AU560757B2 (en) Pharmaceutical compositions containing 3-hydroxybutanoic acid or a salt derived from this acid, and compounds derived from 3-hydroxybutanoic acid which can be used as medicaments
NZ506329A (en) Inhibitors of phospholipase enzymes
DK1161452T3 (da) Kovalent forbundne insulindimerer
HN2000000109A (es) Trifluorbutenos nematicidas
DE602004021472D1 (en) Pyrimiidinverbindungen
CY1108127T1 (el) Μεθοδοι για την προστασια αλλογενους μοσχευματος παγκρεατικων νησιδιων με χρηση διαλυτων μοριων μεταλλακτων ctla4
PL343495A1 (en) Heterocyclically substituted amides used as calpain inhibitors
ATE148130T1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
BR0007589A (pt) Inibidores da proliferação de células
DK0525123T3 (da) Antiatherosklerotiske og antithrombotiske 1-benzopyran-4-oner og 2-amino-1,3-benzoxazin-4-oner
ES2243579T3 (es) Derivados de pirazolopirideno.
ATE338047T1 (de) Stickstoffbasierte camptothecin-derivate
BRPI0308606B8 (pt) compostos derivados de hemiasterlina e composição farmacêutica compreendendo os mesmos
ATE99931T1 (de) Inhibitoren fuer zellenzuwachs und methoden fuer krebsbehandlung.
ID22718A (id) Senyawa-senyawa tetrahidropirido
ES2169022T3 (es) Utilizacion de derivados de (piridil-metil-sulfinil)-1-h-bencimidazol para el tratamiento de enfermedades provocadas por helicobacter.
ES2185196T3 (es) Un procedimiento para la preparacion de tetraazamacrociclos.
BR0308601A (pt) inibidores de carboxipeptidase b de plasma
CY1106051T1 (el) ΔΙΑΔΙΚΑΣΙΑ ΓΙΑ ΤΗΝ ΠΑΡΑΓΩΓΗ Ν-ΠΡΟΣΤΑΤΕΥΜΕΝΩΝ ΑΖΕΤΙΔΙΝΟ-2-ΚΑΡΒΟΞΥΛΙΚΩΝ ΟΞΕΩΝ (AzeOHs)
ES2037003T3 (es) Procedimiento para preparar peptidos empleando percloratos.
DE60014915D1 (de) Hypoxanthin- und thiohypxanthin-verbindungen
PL334624A1 (en) Novel compounds of 8h-thiene-/2,3-b/pyrolysin-8-one, method of obtaining them and pharmaceutic compositions containing such compounds
ES2127516T3 (es) Peptidos para inhibir la liberacion de pepsina.
DK1406627T3 (da) Pyridin-2-yl-methylamin-derivater til behandling af afhængighed af opioider